Share: Facebook Twitter GooglePLus LinkedIn
Activity Provided By:

ACHL

Highlights from the 2018 C3 Symposium on the long-term effects of emerging cholesterol therapies in statin resistant patients and strategies for their management.

Access Activity

Overview / Abstract:

As presented at the 2018 C3 annual meeting, clinicians can learn about strategies to effectively apply new cholesterol therapies in diverse patient populations, clinical implications of the latest outcomes data from the FOURIER, ODYSSEY and SPIRE Trials, and access, cost, and non-adherence challenges of PCSK9 inhibitor therapy.

Expiration

Jul 26, 2019

Discipline(s)

Physician CME

Format

Webinar / Webcast / Video

Credits / Hours

1.25

Accreditation

ACHL designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Is This Activity Certified for "Live" Credit?

YES

Presenters / Authors / Faculty

Chairperson:
Peter Libby, MD
Mallinckrodt Professor of Medicine,
Harvard Medical School
Cardiovascular Specialist, Brigham and Women’s Hospital
Boston, Massachusetts

Co-Chairperson:
Raj Dave, MD, FACC, FSCAI
Chief Medical Executive,
Holy Spirit Cardiovascular Institute
Chairman, Department of Cardiology
Director, Cardiac Catheterization Laboratories
The Ortenzio Heart Center at Holy Spirit Hospital
Camp Hill, Pennsylvania

Faculty:
Alan Brown, MD
Director, Division of Cardiology
Advocate Heart Institute at Lutheran General Hospital
President, National Lipid Society
Park Ridge, Illinois
Nihar Desai, MD, MPH
Assistant Professor of Medicine
Yale School of Medicine
West Haven, Connecticut
Dinesh Kalra, MD, FACC
Assistant Professor
Rush University Medical Center
Chicago, Illinois

Activity Specialities / Related Topics

Cardiology / Cardiovascular

Sponsors / Supporters / Grant Providers

Sponsored by the Academy for Continued Healthcare Learning and Interventional Academy

Supported by an educational grant from Sanofi-Regeneron Alliance

Keywords / Search Terms

ACHL PCSK9 inhibitors, dyslipidemia, hyperlipidemia, FOURIER, ODYSSEY, LDL-C, ACS, CME, CE, Continuing Medical Education, Online Learning, Cardiology, Interventional Cardiology, Cardiovascular Free CE CME Live CE CME

Access Activity

RXinsider, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps. RXinsider, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map.